表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)是EGFR基因突变晚期非小细胞癌(non-small cell lung cancer, NSCLC)患者一线标准治疗方案, 但是临床实践中, 疗效差异较大。本项实验拟研究治疗前血清细胞角蛋白19片段(cytokeratin-19 fragments, CYFRA21-1)和癌胚抗原(carcinoembryonic antigen, CEA)的水平是否与EGFR-TKIs疗效有关。. This evidence concerns the gene KRT19 and non-small cell lung carcinoma.